{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:57:25Z","timestamp":1785473845928,"version":"3.56.0"},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T00:00:00Z","timestamp":1494374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Efficacy and safety profiles of biologics have been established for moderate to severe psoriasis. However, inefficacy or adverse events sometimes require changing the treatment to other biologics. Here, we examine the effectiveness of this strategy. We retrospectively investigated cases requiring switching biologics. We enrolled 275 psoriatic patients treated with biologics between January 2010 and December 2014 in our hospital. Of these, 51 required a switch to another biologic. First\u2010line therapies were infliximab (<jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content>,<jats:italic> n<\/jats:italic> = 26), adalimumab (<jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content>,<jats:italic> n<\/jats:italic> = 18) and ustekinumab (<jats:styled-content style=\"fixed-case\">UST<\/jats:styled-content>,<jats:italic> n<\/jats:italic> = 7), and second\u2010line therapies were <jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content> (<jats:italic>n<\/jats:italic> = 5), <jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content> (<jats:italic>n<\/jats:italic> = 21) and <jats:styled-content style=\"fixed-case\">UST<\/jats:styled-content> (<jats:italic>n<\/jats:italic> = 25). Reasons for switching were inefficacy (<jats:italic>n<\/jats:italic> = 38), adverse events (<jats:italic>n<\/jats:italic> = 11) and others (<jats:italic>n<\/jats:italic> = 2). The details were primary failure (<jats:italic>n = 15<\/jats:italic>), secondary failure (<jats:italic>n<\/jats:italic> = 23) and infusion reactions (<jats:italic>n<\/jats:italic> = 8). In 49 patients who switched biologics due to inefficacy and adverse events, the mean Psoriasis Area and Severity Index (<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>) score at week 16 was 4.3 for first\u2010line therapies and 2.9 for second\u2010line therapies (<jats:italic>P &lt; 0.05<\/jats:italic>). Switching to a second biologic therapy to address the first's inefficacy or adverse events often results in significant improvement in moderate to severe psoriasis.<\/jats:p>","DOI":"10.1111\/1346-8138.13860","type":"journal-article","created":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T08:22:43Z","timestamp":1494404563000},"page":"1015-1019","source":"Crossref","is-referenced-by-count":54,"title":["Switching of biologics in psoriasis: Reasons and results"],"prefix":"10.1111","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4435-8536","authenticated-orcid":false,"given":"Hiromi","family":"Honda","sequence":"first","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Umezawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sota","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3890-2830","authenticated-orcid":false,"given":"Koichi","family":"Yanaba","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Fukuchi","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0125-8930","authenticated-orcid":false,"given":"Yoshimasa","family":"Nobeyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-3182","authenticated-orcid":false,"given":"Akihiko","family":"Asahina","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemi","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041320"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2010.04.014"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.02.021"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00748.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01347.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37876"},{"key":"e_1_2_6_10_1","first-page":"396","article-title":"An open\u2010label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab","volume":"10","author":"Vender R","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09950.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/11310770-000000000-00000"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.208"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12353"},{"issue":"257","key":"e_1_2_6_15_1","first-page":"e3","article-title":"Efficacy of switching between tumor necrosis factor\u2010alfa inhibitors in psoriasis: results from the Italian Psocare registry","volume":"70","author":"Piaserico S","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203018"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03944.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.12.003"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.03.009"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.10.020"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2014.952611"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199010060-00008"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.09.040"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2011.593489"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.800184"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.13860","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.13860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:48:29Z","timestamp":1695548909000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.13860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,10]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/1346-8138.13860"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.13860","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,10]]}}}